TORONTO, ON / ACCESSWIRE / November 15, 2016 / Profound Medical Corp. (TSX-V: PRN) will host a conference call and webcast to
discuss the results of the third quarter 2016, to be held Wednesday, November 16, 2016 at 4:30 PM Eastern Time.
Live Event Information
To participate, connect approximately 5 to 10 minutes before the beginning of the event.
- Date, Time: November 16, 2016 at
4:30 PM ET - Toll Free: 877-407-9210 - International: 201-689-8049 - Live Webcast: www.investorcalendar.com/IC/CEPage.asp?ID=175406
or profoundmedical.com
Replay Information
The replay will be available beginning approximately 2 hours after the completion of the live event, ending at midnight Eastern
on December 16, 2016.
- Toll Free: 877-481-4010 - International: 919-882-2331 - Replay ID#: 10119 - Webcast:
www.investorcalendar.com or profoundmedical.com
About Profound Medical Corp.
The Profound Medical team is committed to the effort to achieve a new therapeutic standard in prostate cancer. For the millions
of men currently living with prostate cancer, and the thousands more who are diagnosed with it every year, current treatment
options often mean having to make difficult choices based on potential side effects that can significantly impact quality of life.
Our mission is to profoundly change the standard of care by creating a tomorrow where clinicians can confidently ablate cancerous
prostate tissue with precision, while actively protecting critical anatomy from potential side effects; a tomorrow where patients
have access to a safe, fast and effective treatment option, so they can quickly return to their daily lives.
Established in 2008, Profound Medical is commercializing a novel technology, TULSA-PRO, which combines real-time Magnetic
Resonance Imaging with transurethral, robotically-driven therapeutic ultrasound and closed-loop thermal feedback control that is
designed to provide precise ablation of the prostate while simultaneously protecting critical surrounding anatomy from potential
side effects. TULSA-PRO is CE Marked and Profound is sponsoring a multicenter, prospective FDA-registered clinical trial, TACT,
which is designed to further demonstrate the safety and effectiveness of this innovative technology.
SOURCE: Investor Calendar
